{"title":"罗哌卡因能否安全有效地用于腹腔镜胃肠手术后的镇痛?","authors":"Yan Jun , Jin Jue , Zheng Min-hua , Yu Bu-wei","doi":"10.1016/j.acpain.2008.10.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p><span>This prospective observer-blinded clinical trial<span> is designed to evaluate the effectiveness and the safety of 0.5% ropivacaine 30</span></span> <!-->ml (150<!--> <span><span>mg) administrated via subcutaneous infiltration at incision with or without combination of intraperitoneal spray for analgesia after laparoscopically assisted </span>gastrointestinal surgery.</span></p></div><div><h3>Methods</h3><p><span>Ninety ASA grade I–III patients were randomized into three groups: Group R1 (29 patients) in which patients received infiltration of 0.5% ropivacaine 30</span> <!-->ml at all incision sites before the suturing, Group R2 (31 patients) in which patients received 0.5% ropivacaine 20<!--> <!-->ml at all incision sites and intraperitoneal spray of 0.5% ropivacaine 10<!--> <span>ml before the suturing and Group C (30 patients) in which patients received no ropivacaine as control. VAS scores at rest and during coughing were recorded immediately after emergence (H0), at 2</span> <!-->h (H2), 4<!--> <!-->h (H4), 6<!--> <!-->h (H6) and 24<!--> <span>h (H24) after operation. Serum cortisol concentration of cortisol was measured preoperatively (F0) and 2</span> <span>h after operation (F2). Subcutaneous pethidine<span> blouses given for additional pain treatment were counted for the first 24</span></span> <!-->h after operation and follow-up examination of incisions were performed at the 1st, 4th, 7th day after operation.</p></div><div><h3>Results</h3><p>Within 6<!--> <!-->h postoperatively, the patients in Groups R1 and R2 reported significantly lower VAS scores at rest and during coughing than those in Group C (<em>P</em> <!--><<!--> <!-->0.05). Serum cortisol concentrations at 2<!--> <!-->h (F2) after operation were significantly lower in Group R2 than in Group C. There was no difference among the three groups in administration of pethidine boluses within 6<!--> <!-->h and 24<!--> <!-->h after the surgery. In this trial, no neurological or cardiac complications were observed in any patient.</p></div><div><h3>Conclusion</h3><p>Thirty millilitres of 0.5% ropivacaine can be used effectively and safely for pain control in the early hours after laparoscopically assisted gastrointestinal surgery and subcutaneous infiltration at incision sites combined with intraperitoneal spray can provide more complete analgesia. However, analgesia provided by ropivacaine via subcutaneous infiltration at incision sites with or without intraperitoneal spray would gradually become less effective 6<!--> <!-->h after the operation, hence requiring additional pain treatment.</p></div>","PeriodicalId":100023,"journal":{"name":"Acute Pain","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2009-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.acpain.2008.10.002","citationCount":"0","resultStr":"{\"title\":\"Can ropivacaine be effectively and safely used in analgesia after laparoscopically assisted gastrointestinal surgery?\",\"authors\":\"Yan Jun , Jin Jue , Zheng Min-hua , Yu Bu-wei\",\"doi\":\"10.1016/j.acpain.2008.10.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p><span>This prospective observer-blinded clinical trial<span> is designed to evaluate the effectiveness and the safety of 0.5% ropivacaine 30</span></span> <!-->ml (150<!--> <span><span>mg) administrated via subcutaneous infiltration at incision with or without combination of intraperitoneal spray for analgesia after laparoscopically assisted </span>gastrointestinal surgery.</span></p></div><div><h3>Methods</h3><p><span>Ninety ASA grade I–III patients were randomized into three groups: Group R1 (29 patients) in which patients received infiltration of 0.5% ropivacaine 30</span> <!-->ml at all incision sites before the suturing, Group R2 (31 patients) in which patients received 0.5% ropivacaine 20<!--> <!-->ml at all incision sites and intraperitoneal spray of 0.5% ropivacaine 10<!--> <span>ml before the suturing and Group C (30 patients) in which patients received no ropivacaine as control. VAS scores at rest and during coughing were recorded immediately after emergence (H0), at 2</span> <!-->h (H2), 4<!--> <!-->h (H4), 6<!--> <!-->h (H6) and 24<!--> <span>h (H24) after operation. Serum cortisol concentration of cortisol was measured preoperatively (F0) and 2</span> <span>h after operation (F2). Subcutaneous pethidine<span> blouses given for additional pain treatment were counted for the first 24</span></span> <!-->h after operation and follow-up examination of incisions were performed at the 1st, 4th, 7th day after operation.</p></div><div><h3>Results</h3><p>Within 6<!--> <!-->h postoperatively, the patients in Groups R1 and R2 reported significantly lower VAS scores at rest and during coughing than those in Group C (<em>P</em> <!--><<!--> <!-->0.05). Serum cortisol concentrations at 2<!--> <!-->h (F2) after operation were significantly lower in Group R2 than in Group C. There was no difference among the three groups in administration of pethidine boluses within 6<!--> <!-->h and 24<!--> <!-->h after the surgery. In this trial, no neurological or cardiac complications were observed in any patient.</p></div><div><h3>Conclusion</h3><p>Thirty millilitres of 0.5% ropivacaine can be used effectively and safely for pain control in the early hours after laparoscopically assisted gastrointestinal surgery and subcutaneous infiltration at incision sites combined with intraperitoneal spray can provide more complete analgesia. However, analgesia provided by ropivacaine via subcutaneous infiltration at incision sites with or without intraperitoneal spray would gradually become less effective 6<!--> <!-->h after the operation, hence requiring additional pain treatment.</p></div>\",\"PeriodicalId\":100023,\"journal\":{\"name\":\"Acute Pain\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.acpain.2008.10.002\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acute Pain\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1366007108001745\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acute Pain","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1366007108001745","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的本前瞻性观察盲临床试验旨在评价0.5%罗哌卡因30 ml (150 mg)经切口皮下浸润联合或不联合腹腔内喷雾剂用于腹腔镜辅助胃肠手术后镇痛的有效性和安全性。方法90例ASA I-III级患者随机分为3组:R1组(29例)在缝合前所有切口部位浸润0.5%罗哌卡因30 ml; R2组(31例)在缝合前所有切口部位浸润0.5%罗哌卡因20 ml,并腹腔喷注0.5%罗哌卡因10 ml; C组(30例)不注射罗哌卡因作为对照。术后即刻(H0)、术后2 h (H2)、4 h (H4)、6 h (H6)、24 h (H24)分别记录静息和咳嗽时VAS评分。术前(F0)和术后2 h (F2)测定血清皮质醇浓度。术后24 h给予皮下哌替啶治疗,术后第1、4、7天随访切口检查。结果术后6 h内,R1组和R2组患者休息时和咳嗽时的VAS评分明显低于C组(P <0.05)。R2组术后2 h (F2)血清皮质醇浓度明显低于c组。术后6 h和24 h内三组患者使用哌替啶的情况无显著差异。在这项试验中,没有观察到任何患者出现神经或心脏并发症。结论应用0.5%罗哌卡因30 ml可有效、安全地控制腹腔镜胃肠手术术后早期疼痛,切口皮下浸润联合腹腔内喷剂可提供更完全的镇痛效果。然而,罗哌卡因经切口皮下浸润或不经腹腔内喷雾剂提供的镇痛效果在术后6小时后逐渐减弱,因此需要额外的疼痛治疗。
Can ropivacaine be effectively and safely used in analgesia after laparoscopically assisted gastrointestinal surgery?
Objective
This prospective observer-blinded clinical trial is designed to evaluate the effectiveness and the safety of 0.5% ropivacaine 30 ml (150 mg) administrated via subcutaneous infiltration at incision with or without combination of intraperitoneal spray for analgesia after laparoscopically assisted gastrointestinal surgery.
Methods
Ninety ASA grade I–III patients were randomized into three groups: Group R1 (29 patients) in which patients received infiltration of 0.5% ropivacaine 30 ml at all incision sites before the suturing, Group R2 (31 patients) in which patients received 0.5% ropivacaine 20 ml at all incision sites and intraperitoneal spray of 0.5% ropivacaine 10 ml before the suturing and Group C (30 patients) in which patients received no ropivacaine as control. VAS scores at rest and during coughing were recorded immediately after emergence (H0), at 2 h (H2), 4 h (H4), 6 h (H6) and 24 h (H24) after operation. Serum cortisol concentration of cortisol was measured preoperatively (F0) and 2h after operation (F2). Subcutaneous pethidine blouses given for additional pain treatment were counted for the first 24 h after operation and follow-up examination of incisions were performed at the 1st, 4th, 7th day after operation.
Results
Within 6 h postoperatively, the patients in Groups R1 and R2 reported significantly lower VAS scores at rest and during coughing than those in Group C (P < 0.05). Serum cortisol concentrations at 2 h (F2) after operation were significantly lower in Group R2 than in Group C. There was no difference among the three groups in administration of pethidine boluses within 6 h and 24 h after the surgery. In this trial, no neurological or cardiac complications were observed in any patient.
Conclusion
Thirty millilitres of 0.5% ropivacaine can be used effectively and safely for pain control in the early hours after laparoscopically assisted gastrointestinal surgery and subcutaneous infiltration at incision sites combined with intraperitoneal spray can provide more complete analgesia. However, analgesia provided by ropivacaine via subcutaneous infiltration at incision sites with or without intraperitoneal spray would gradually become less effective 6 h after the operation, hence requiring additional pain treatment.